Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xemilofiban SCHEMBL5163315 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| Xemilofiban SCHEMBL609244 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| Xemilofiban SCHEMBL27987260 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2B | |
| SCHEMBL7351416 | 0.90 | ITGB3 (0.81) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| SCHEMBL7353828 | 0.87 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7346572 | 0.87 | ITGB3 (0.77) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| SCHEMBL7346651 | 0.86 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7348945 | 0.86 | ITGB3 (0.75) | ITGB3ITGA2B | |
| SCHEMBL7355439 | 0.85 | ITGB3 (0.79) | ITGB3ITGA2B | |
| SCHEMBL7346593 | 0.85 | ITGB3 (0.74) | ITGB3ITGA2BLMNAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-2214573-B1 | SYSTEM FOR TREATMENT AND IMAGING USING ULTRASONIC ENERGY AND MICROBUBBLES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2019-07-03 | — | — | EP | claimed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | claimed |
| US-9770349-B2 | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-09-26 | — | — | US | claimed |
| CN-101680018-B | Application of the endothelium/smooth muscle cell co-culture model of extracorporeal hemodynamic in the new therapeutic targets of identification vascular diseases | 海莫希尔有限责任公司 | 2017-03-15 | — | — | CN | claimed |
| US-9526922-B2 | System for treatment and imaging using ultrasonic energy and microbubbles and related method thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-12-27 | — | — | US | claimed |
| US-9381243-B2 | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof | RIGSHOSPITALET (DK) | 2016-07-05 | — | — | US | claimed |
| WO-2015103643-A2 | INTEGRIN ANTAGONISTS | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-09 | — | — | WO | claimed |
| EP-2118268-B1 | USE OF AN IN VITRO HEMODYNAMIC ENDOTHELIAL/SMOOTH MUSCLE CELL CO-CULTURE MODEL TO IDENTIFY NEW THERAPEUTIC TARGETS FOR VASCULAR DISEASE | HEMOSHEAR LLC (US) | 2015-07-08 | — | — | EP | claimed |
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-6346517-B1 | ADMINISTERING TINZAPARIN AND ROXIFIBAN | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-12 | — | — | US | claimed |
| JP-2001524534-A | — | — | 2001-12-04 | — | — | JP | claimed |
| EP-1035868-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | Wiemann, Gundula (DE) | 2000-09-20 | — | — | EP | claimed |
| WO-2000053168-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| EP-0839128-B1 | PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE | SEARLE & CO (US) | 2000-04-05 | — | — | EP | claimed |
| WO-1999027962-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | WIEMANN GUNDULA (DE) | 1999-06-10 | — | — | WO | claimed |
| EP-0839128-A1 | PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE | G.D. SEARLE & CO. (US) | 1998-05-06 | — | — | EP | claimed |
| WO-1997035592-A1 | IIB/IIIA ANTAGONISTS CO-ADMINISTERED WITH ASPIRIN AND/OR HEPARIN | G.D. SEARLE & CO. (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997003947-A1 | PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE | G.D. SEARLE & CO. (US) | 1997-02-06 | — | — | WO | claimed |
| US-5536869-A | Process for the preparation of ethyl 3S-[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate | G. D. SEARLE & CO. (US) | 1996-07-16 | — | — | US | claimed |